Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing cancer treatments in the United States, Europe and other international markets. Clovis’ development programs are targeted at specific subsets of cancer, combining precision medicine with companion diagnostics to direct therapeutics to those patients most likely to benefit from their use. Clovis believes this approach to precision medicine – to deliver the right dr
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 21, 2017--
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that the
underwriters of its recently announced public offering of its common
stock have exercised in full their option to purchase an additional
The offering, including the sale of the additional shares, is expected
to close on June 26, 2017, subject to customary closing conditions.
Clovis Oncology intends to use th...
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 20, 2017--
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today the pricing of an
underwritten public offering of 3,409,091 shares of its common stock at
$88.00 per share, before underwriting discounts and commissions. The
size of the offering was upsized from $250 million to $300 million. In
addition, the underwriters have a 30-day option to purchase up to an
additional 511,363 shares of common stock from Clovis Onco...
BOULDER, Colo.--(BUSINESS WIRE)--Jun. 19, 2017--
Clovis Oncology, Inc. (NASDAQ:CLVS) announced today that it has
commenced an underwritten public offering of shares of its common stock
to raise aggregate proceeds of approximately $250 million. All shares of
the common stock to be sold in the offering will be offered by Clovis
Clovis Oncology intends to use the net proceeds of the offering for
general corporate purposes, including...
Sign up to receive email alerts whenever Clovis Oncology, Inc. posts new information to the site. Just enter your email address and click Submit.
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.